CONFIDENTIAL DISCLOSURE AGREEMENTConfidential Disclosure Agreement • May 2nd, 2008 • Sirtris Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS CONFIDENTIAL DISCLOSURE AGREEMENT (the “Agreement”) is made and entered into as of the sixth (6th) day of February, 2006 (the “Effective Date”), by and between Sirtris Pharmaceuticals, Inc., a Delaware corporation having offices at 790 Memorial Drive, Suite 104, Cambridge, MA 02139 (“Sirtris”) and SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a Pennsylvania corporation having offices at Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (“GSK”).
RESEARCH ADVISORY AND CONSULTING AGREEMENT BETWEEN DAVID SINCLAIR, Ph.D. AND SMITHKLINE BEECHAM CORPORATION, d/b/a GLAXOSMITHKLINEAnd Consulting Agreement • May 2nd, 2008 • Sirtris Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (“Agreement”) shall be effective as of date on which the transaction under which Sirtris Pharmaceuticals, Inc. is acquired by GSK is consummated (the “Effective Date”) and shall set forth, together with Appendices A, B, and C which are attached hereto and hereby incorporated by reference, the full terms and conditions which shall apply to the consulting and advisory services to be provided hereunder by David Sinclair, Ph.D. residing at 43 Newbrook Circle, Chestnut Hill, Massachusetts 02467 (hereinafter “Consultant”) as a consultant to the [Sirtris] Discovery Performance Unit (the “Unit”) of SmithKline Beecham Corporation, d/b/a GlaxoSmithKline, a Pennsylvania Corporation with a place of business at One Franklin Plaza, Philadelphia, PA 19101 (hereinafter “GSK”). Whereas, GSK and Consultant, desiring and intending to be legally bound by the terms and conditions hereof, do hereby enter into this Agreement as of the Effective Date. This Agreement shall terminate a
